Buys | $0 | 0 | 0 |
Sells | $74,870,566 | 54 | 100 |
Ware Olivia C | director | 0 | $0 | 2 | $1.16M | $-1.16M |
Gilson Michelle | CHIEF FINANCIAL OFFICER | 0 | $0 | 10 | $6.58M | $-6.58M |
Elghandour Rami | SEE REMARKS | 0 | $0 | 6 | $8.56M | $-8.56M |
Patel Kavita | director | 0 | $0 | 17 | $8.66M | $-8.66M |
Heery Christopher | CHIEF MEDICAL OFFICER | 0 | $0 | 18 | $14.34M | $-14.34M |
Carroll Jill | director | 0 | $0 | 1 | $35.58M | $-35.58M |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid …
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $74.87M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $91.25M and sold $68.36M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
2025-02-26 | Sale | Elghandour Rami | SEE REMARKS | 38,300 0.0727% | $62.02 | $2.38M | +11.06% | |
2025-02-25 | Sale | Patel Kavita | director | 1,500 0.0027% | $63.16 | $94,740 | +9.66% | |
2025-02-24 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 10,155 0.0188% | $63.79 | $647,773 | +8.76% | |
2025-02-04 | Sale | Patel Kavita | director | 1,500 0.0028% | $64.57 | $96,855 | -3.09% | |
2025-01-14 | Sale | Patel Kavita | director | 1,500 0.0028% | $65.87 | $98,801 | +1.86% | |
2025-01-08 | Sale | Elghandour Rami | SEE REMARKS | 13,837 0.0259% | $73.69 | $1.02M | -8.87% | |
2025-01-08 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 3,553 0.0066% | $73.69 | $261,831 | -8.87% | |
2025-01-08 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 3,997 0.0075% | $73.69 | $294,551 | -8.87% | |
2025-01-07 | Sale | Elghandour Rami | SEE REMARKS | 16,474 0.03% | $75.53 | $1.24M | -14.54% | |
2025-01-07 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 4,230 0.0077% | $75.53 | $319,485 | -14.54% | |
2025-01-07 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 14,012 0.0255% | $75.68 | $1.06M | -14.54% | |
2025-01-06 | Sale | Elghandour Rami | SEE REMARKS | 15,111 0.0287% | $77.17 | $1.17M | -11.97% | |
2025-01-06 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $77.17 | $229,571 | -11.97% | |
2025-01-06 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 5,621 0.0107% | $77.17 | $433,755 | -11.97% | |
2025-01-03 | Sale | Elghandour Rami | SEE REMARKS | 15,112 0.0284% | $79.55 | $1.2M | -16.33% | |
2025-01-03 | Sale | Heery Christopher | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $79.55 | $236,656 | -16.33% | |
2025-01-03 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 5,622 0.0106% | $79.55 | $447,219 | -16.33% | |
2024-12-24 | Sale | Patel Kavita | director | 1,500 0.0028% | $76.97 | $115,451 | -13.75% | |
2024-12-03 | Sale | Patel Kavita | director | 1,500 0.0028% | $91.88 | $137,818 | -22.96% | |
2024-11-15 | Sale | Gilson Michelle | CHIEF FINANCIAL OFFICER | 1,761 0.003% | $88.87 | $156,508 | -19.48% |
Carroll Jill | director | 1479148 2.6921% | $106.03M | 1 | 6 | +6.58% |
New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.2766% | $483.5M | 2 | 0 | +40.21% |
Novo Holdings A/S | 10 percent owner | 4016878 7.3109% | $287.93M | 1 | 0 | +6.58% |
SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 3.019% | $118.9M | 1 | 1 | +6.58% |
BASKETT FOREST | director | 0 0% | $0 | 1 | 1 | +73.84% |
$52,263,649 | 70 | 1.18% | $4.36B | |
$140,165,669 | 33 | 85.24% | $3.32B | |
$11,859,102 | 17 | 18.62% | $5.25B | |
$74,605,681 | 14 | 47.06% | $3.61B | |
$57,686,748 | 13 | 21.11% | $4.3B |
Increased Positions | 125 | +63.78% | 13M | +26.37% |
Decreased Positions | 83 | -42.35% | 4M | -8.87% |
New Positions | 50 | New | 8M | New |
Sold Out Positions | 27 | Sold Out | 2M | Sold Out |
Total Postitions | 238 | +21.43% | 58M | +17.5% |
Fmr Llc | $515,749.00 | 14.47% | 7.96M | +1M | +22.8% | 2024-12-31 |
Gilead Sciences, Inc. | $435,642.00 | 12.22% | 6.72M | +7M | New | 2024-12-31 |
Paradigm Biocapital Advisors Lp | $283,367.00 | 7.95% | 4.37M | +371,601 | +9.29% | 2024-12-31 |
Blackrock, Inc. | $249,818.00 | 7.01% | 3.85M | -392,671 | -9.25% | 2024-12-31 |
Nea Management Company, Llc | $242,768.00 | 6.81% | 3.75M | 0 | 0% | 2024-12-31 |
Perceptive Advisors Llc | $225,502.00 | 6.33% | 3.48M | -409,781 | -10.54% | 2024-12-31 |
Vanguard Group Inc | $215,857.00 | 6.06% | 3.33M | +867,996 | +35.25% | 2024-12-31 |
Ra Capital Management, L.P. | $180,675.00 | 5.07% | 2.79M | +935,848 | +50.55% | 2024-12-31 |
Sr One Capital Management, Lp | $152,109.00 | 4.27% | 2.35M | 0 | 0% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $137,504.00 | 3.86% | 2.12M | +220,711 | +11.61% | 2024-12-31 |